Printer Friendly

-Bayer's Riociguat Meets Primary Endpoint in Pivotal Phase III Study in Patients with Pulmonary Arterial Hypertension.

Travel Business Review-October 22, 2012--Bayer's Riociguat Meets Primary Endpoint in Pivotal Phase III Study in Patients with Pulmonary Arterial Hypertension(C)2012] ENPublishing - http://www.enpublishing.co.uk

ENP Newswire - 22 October 2012

Release date- 22102012 - Berlin, - Bayer HealthCare today announced positive data for riociguat from the pivotal Phase III study PATENT-1.

The study met its primary endpoint by demonstrating a statistically significant improvement in the six-minute walk test (6MWT), a predictor of improved outcome in patients suffering from pulmonary arterial hypertension (PAH).(1,2) Patients treated with riociguat showed an improvement of 36 meters (95%-CI [20-52 meters] p

((Distributed via M2 Communications - http://www.m2.com)).END.PUB430>PDOctober 22, 2012>JNTRAVEL BUSINESS REVIEW.PRICEDATENOT APPLICABLE.DAY
COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Travel Business Review (TBR)
Date:Oct 22, 2012
Words:119
Previous Article:-BIOTA -Merger update, determination of VWAP & share ratios.
Next Article:-Bayer's Xarelto (Rivaroxaban) Recommended for EU Approval for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein...

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters